Update on the effectiveness of COVID-19 vaccines on different variants of SARS-CoV-2
N Firouzabadi, P Ghasemiyeh, F Moradishooli… - International …, 2023 - Elsevier
It has been more than three years since the first emergence of coronavirus disease 2019
(COVID-19) and millions of lives have been taken to date. Like most pandemics caused by …
(COVID-19) and millions of lives have been taken to date. Like most pandemics caused by …
The vaccine world of COVID-19: India's Contribution
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) eruption has left not
only illness and mortality in its wake, but also an overwhelming threat to health policy …
only illness and mortality in its wake, but also an overwhelming threat to health policy …
Immunogenicity and reactogenicity of an inactivated SARS-CoV-2 vaccine (BBV152) in children aged 2–18 years: interim data from an open-label, non-randomised …
KM Vadrevu, S Reddy, H Jogdand… - The Lancet Infectious …, 2022 - thelancet.com
Background Despite having milder symptoms than adults, children are still susceptible to
and can transmit SARS-CoV-2. Vaccination across all age groups is therefore necessary to …
and can transmit SARS-CoV-2. Vaccination across all age groups is therefore necessary to …
Booster dose of the inactivated COVID-19 vaccine BBV152 (Covaxin) enhances the neutralizing antibody response against alpha, Beta, Delta and omicron variants of …
The neutralizing antibody responses were significantly elevated after 3rd dose of
BBV152/Covaxin against the B. 1 (19.11 fold) variant including Delta (16.51 fold), Beta …
BBV152/Covaxin against the B. 1 (19.11 fold) variant including Delta (16.51 fold), Beta …
A comprehensive review of BBV152 vaccine development, effectiveness, safety, challenges, and prospects
F Dotiwala, AK Upadhyay - Frontiers in Immunology, 2022 - frontiersin.org
The world has responded to the COVID-19 pandemic with unprecedented speed and vigor
in the mass vaccination campaigns, targeted to reduce COVID-19 severity and mortality …
in the mass vaccination campaigns, targeted to reduce COVID-19 severity and mortality …
Application of traditional vaccine development strategies to SARS-CoV-2
Over the past 150 years, vaccines have revolutionized the relationship between people and
disease. During the COVID-19 pandemic, technologies such as mRNA vaccines have …
disease. During the COVID-19 pandemic, technologies such as mRNA vaccines have …
COVID-19 Vaccines—All You Want to Know
AA Shishido, AH Barnes, S Narayanan… - … in Respiratory and …, 2023 - thieme-connect.com
The severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) pandemic has led to
an unprecedented public health crisis. The collective global response has led to production …
an unprecedented public health crisis. The collective global response has led to production …
Immunity against the Omicron variant from vaccination, recovery, or both
M Gandhi - Clinical Infectious Diseases, 2022 - academic.oup.com
See the Major Article by Data comparing the protective immunity from coronavirus disease
2019 (COVID-19) recovery versus 2-dose vaccination are limited in the Omicron variant era …
2019 (COVID-19) recovery versus 2-dose vaccination are limited in the Omicron variant era …
SARS CoV-2 Omicron (B. 1.1. 529) Recent Updates and Challenges Worldwide
The current world is plagued by unpredictability as a result of various COVID-19 variants.
The current variants of concern (VOCs) are B. 1.1. 7 (Alpha), B. 1.351 (Beta), P. 1 (Gamma) …
The current variants of concern (VOCs) are B. 1.1. 7 (Alpha), B. 1.351 (Beta), P. 1 (Gamma) …
Efficacy and Adverse Effects of the Most Common COVID-19 Vaccines: a Rapid Review Study
A Soleymanitabar, MA Gharekhanloo… - Journal of Applied …, 2022 - biotechrep.ir
COVID-19 raised a flood of events all through the world in multiple fields. Reaching an
agreement to generate and use vaccines against SARSCoV-2 (the cause of COVID-19) was …
agreement to generate and use vaccines against SARSCoV-2 (the cause of COVID-19) was …